Pentaerythritol Tetranitrate
drugOn this page
Also known as CardiacapMycardolPentaerithritol tetranitratePentaerithrityl tetranitratePentaerythrityl tetranitratePentalongPentritol tempulesPeritratePeritrate saTetranitrate de pentaerithrityleTetranitrato de pentaeritritiloSID29215318SID144205177SID144212064
Summary
Pentaerythritol Tetranitrate (CHEMBL466659) is a phase-3 clinical-stage small-molecule vasodilator agent (ATC C01DA55); indicated across 1 condition including cardiovascular disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: C01DA55 (+1 more)
- Indications: 1 condition
- Clinical trials: 2
- Chemistry: 316.14 Da · C5H8N4O12
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL466659 |
| Name | Pentaerythritol Tetranitrate |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 6518 |
| ChEBI | CHEBI:25879 |
| ATC | C01DA55, C01DA05 |
| Molecular formula | C5H8N4O12 |
| Molecular weight | 316.14 |
| InChIKey | TZRXHJWUDPFEEY-UHFFFAOYSA-N |
SMILES: C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O[N+](=O)[O-]
IUPAC name: [3-nitrooxy-2,2-bis(nitrooxymethyl)propyl] nitrate
ChEBI definition: A pentaerythritol nitrate in which all four hydroxy groups of pentaerythritol have been converted to the corresponding nitrate ester. It is a vasodilator with properties similar to those of glyceryl trinitrate, but with a more prolonged duration of action, and is used for treatment of angina pectoris. It is also one of the most powerful high explosives known and is a component of the plastic explosive known as Semtex.
Pharmacological roles (ChEBI): explosive, vasodilator agent.
Also known as: Cardiacap, Mycardol, Pentaerithritol tetranitrate, Pentaerithrityl tetranitrate, Pentaerythritol tetranitrate, Pentaerythrityl tetranitrate, Pentalong, Pentritol tempules, Peritrate, Peritrate sa, Tetranitrate de pentaerithrityle, Tetranitrato de pentaeritritilo
Patent coverage: 11,118 distinct patent families (22,254 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Aldehyde dehydrogenase 1A1.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| ALDH1A1 | 5.8 | Potency | 1585 | nM | CHEMBL_ACT_4134678 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 4 | MONDO:0004995 | EFO:0000319 |
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03669185 | PHASE3 | UNKNOWN | Pentaerithrityl Tetranitrate (PETN) for Secondary Prevention of Intrauterine Growth Restriction |
| NCT00168519 | Not specified | COMPLETED | Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: cardiovascular disorder